Cyclin-Dependent Kinase Inhibitor Seliciclib Shows In Vitro Activity in Diffuse Large B Cell Lymphomas.
Francesco Bertoni(Ente Ospedaliero Cantonale), David E. MacCallum(Cyclacel Pharmaceuticals (United Kingdom)), Andrea Rinaldi(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Carlo C. Catapano(Institute of Oncology Research), Vittoria Martin(University of Insubria), Katia Lacrima(Consiglio per la ricerca in agricoltura e l’analisi dell’economia agraria), Maria Grazia Tibiletti(University of Insubria), Sara Vignati(Institute of Oncology Research)
Cited by 1
Related Papers
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database
|Genetics in Medicine|2019|666
The coding genome of splenic marginal zone lymphoma: activation of <i>NOTCH2</i> and other pathways regulating marginal zone development
|The Journal of Experimental Medicine|2012|378